{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009491","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.702138+00:00","generated_at":"2026-06-04T07:09:30.084552+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Pieris restructures to capture partnered milestones; ends R&D, cuts workforce, cash $26.4M","bullets":["As of Dec 31, 2023, cash and investments $26.4M; cost cuts expected to extend runway into 2027.","All R&D activities to cease by mid-2024; additional workforce and board reductions planned in Q2 2024.","Eligible for up to $75M in near-term milestones from Pfizer, Boston Pharmaceuticals, and Servier partnerships.","Total potential milestones: up to $275M development and over $500M commercial across partnered 4-1BB bispecific programs.","Company may pursue milestone/royalty monetization or cash dividends in future."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009491","json":"https://secwatch.observer/filing/0001437749-24-009491.json","markdown":"https://secwatch.observer/filing/0001437749-24-009491.md","text":"https://secwatch.observer/filing/0001437749-24-009491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924009491/0001437749-24-009491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924009491/pirs20240323_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:09:30.084552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}